Guess which ASX 100 stock is expecting to report a 200% increase in profits

Profit guidance has been unveiled for FY 2024. Let's see what is expected.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Ramsay Health Care Ltd (ASX: RHC) shares are on the slide on Monday.

At the time of writing, the ASX 100 stock is down 1.8% to $44.49.

This compares to the performance of the benchmark ASX 200 index, which is down 2.3%.

A man looking at his laptop and thinking.

Image source: Getty Images

Why is this ASX 100 stock falling?

Investors have been selling the private hospital operator's shares amid market weakness and the release of its profit guidance for FY 2024.

According to the release, subject to finalisation of the accounts and audit sign off, Ramsay is expecting to report a net profit after tax in the range of $884 million to $889 million for the 12 months.

This is up approximately 200% on the $298.1 million that the ASX 100 stock reported a year ago.

However, before you get too excited, there's a very big reason why Ramsay Health Care's profits are up significant year on year.

That reason is the company sold its 50:50 joint venture in Asia, Ramsay Sime Darby (RSD), in December 2023. This has led to it recording an after-tax cash profit on the sale of RSD of $618 million.

Profit from continuing operations

A more accurate representation of its performance in FY 2024 would be its profits from continuing operations.

The ASX 100 stock revealed that its FY 2024 net profit after tax from continuing operations is expected to be in the range of $265 million to $270 million. This compares to $278.2 million in the prior corresponding period.

The result is expected to include non-cash impairments and accelerated write-downs against the book value of underperforming assets in both Ramsay Sante and the UK region of $24.5 million after tax and minority interests.

Also included will be negative net mark to market movements in relation to interest rate swaps in Ramsay Sante's debt facilities of $13.1 million after tax.

Furthermore, as a result of the expected impairment charges and write downs, Ramsay's FY 2024 depreciation, amortisation, and impairments charge is expected to be slightly above the top end of its previously expected range of $1 billion to $1.1 billion at approximately $1.13 billion.

Finally, non-recurring items in total are expected to make a negative contribution to the result of approximately $29.5 million after tax. This compares to a positive contribution of $27.5 million in the prior corresponding period.

Excluding the impact of non-recurring items, its FY 2024 net profit after tax from continuing operations is expected to be in the range of $294 million to $299 million.

Management commented:

The Group's underlying result has been driven by improving activity trends and labour productivity, combined with a focus on sustainable performance acceleration programs and improved tariff indexation.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

ASX share investor sitting with a laptop on a desk, pondering something.
Share Fallers

CSL shares crash to a 9-year low. Is it time to sell off my shares?

What's next for the beaten-down ASX biotech stock?

Read more »

Six smiling health workers pose for a selfie.
Healthcare Shares

This ASX biotech hit a 90% success rate. Can it unlock commercial growth?

Orthocell is already seeing growing adoption, with more than 300 surgeons across over 220 hospitals in Australia using Remplir.

Read more »

Researchers and doctors with futuristic 3D hologram overlay for body anatomy or DNA in hospital clinic.
Healthcare Shares

This ASX biotech is pushing for a Nasdaq listing. Could it reignite investor interest?

The NASDAQ has a reputation for providing a platform for some of the world's most innovative companies.

Read more »

Smiling health care workers in a medical setting.
Healthcare Shares

3 ASX healthcare shares to buy amid sector rout: experts

Healthcare shares have tumbled 36% over the past year amid multiple headwinds for the sector.

Read more »

Person pressing the buy button on a smartphone.
Broker Notes

3 reasons to buy Pro Medicus shares today

A leading analyst believes Pro Medicus shares are now trading at a significant discount.

Read more »

Medical workers examine an x-ray or scan in a hospital laboratory.
Healthcare Shares

This ASX biotech has just announced a major US deal

This company's heart disease technology is gaining traction.

Read more »

Devastated woman sits near smartphone on home kitchen floor troubled with loneliness.
Healthcare Shares

Which beaten down ASX healthcare stock is a better buy right now: Pro Medicus vs Cochlear shares

Which do experts prefer?

Read more »

Health professional working on his laptop.
Healthcare Shares

Already up 42% this year, Morgans says this ASX healthcare stock can continue to rocket

This broker sees big upside for this healthcare stock.

Read more »